{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-004266","form_type":"8-K","ticker":"ULBI","cik":"0000875657","company_name":"ULTRALIFE CORP","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.105047+00:00","generated_at":"2026-06-06T01:46:09.001937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03","bullets":["Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.","Q4 operating income $3.6M vs $0.2M; full-year $9.5M vs $0.1M.","Q4 adjusted EPS $0.18 vs loss of $0.03; full-year adjusted EPS $0.52 vs loss of $0.07.","Medical battery sales highest quarter ever; Battery & Energy gross margin expanded 360 bps to 25.2%.","Backlog $103.5M at year-end; management plans to pay down acquisition debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-004266","json":"https://secwatch.observer/filing/0001437749-24-004266.json","markdown":"https://secwatch.observer/filing/0001437749-24-004266.md","text":"https://secwatch.observer/filing/0001437749-24-004266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/ulbi20240214_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:46:09.001937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"746a8bf6d8b5a3584908df29b35c1e03076c11dd","claim":"ULTRALIFE CORP reported full year ended December 31, 2023 results: revenue $158.6 million, EPS Adjusted EPS of $0.52.","evidence_excerpt":"representing a 134.8% year-over-year increase ● Backlog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: ● Sales of $158.6 million representing a 20.3% year-over-year increase ● Operating income of $9.5 million versus $0.1 million for 2022 ● Adjusted EPS of $0.52 compared to a loss of $0.07 for 2022 ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$158.6 million"},{"label":"EPS","value":"Adjusted EPS of $0.52"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"98fa20ff3831cad9bbcb7a23d7c0d60292252d4f","claim":"ULTRALIFE CORP reported fourth quarter ended December 31, 2023 results: revenue $44.5 million, net income $2.9 million, EPS $0.17 per diluted share.","evidence_excerpt":"15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $3.6 million versus $0.2 million for the 2022 fourth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$44.5 million"},{"label":"Net income","value":"$2.9 million"},{"label":"EPS","value":"$0.17 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}